Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647993 | 0.93 | PTPN1 (0.59) | PTPN1PTPN2 | |
| SCHEMBL12971423 | 0.92 | PTPN1 (0.56) | PTPN1PTPN2 | |
| SCHEMBL1908736 | 0.91 | PTPN1 (0.54) | PTPN1PTPN2 | |
| SCHEMBL2937148 | 0.85 | PTPN1 (0.57) | PTPN1PTPN2 | |
| SCHEMBL649308 | 0.84 | PTPN1 (0.56) | PTPN1PTPN2 | |
| SCHEMBL12971487 | 0.83 | PTPN1 (0.53) | PTPN1PTPN2 | |
| SCHEMBL2937145 | 0.83 | PTPN1 (0.55) | PTPN1PTPN2 | |
| SCHEMBL647411 | 0.82 | PTPN1 (0.74) | PTPN1PTPN2 | |
| SCHEMBL649399 | 0.81 | PTPN1 (0.64) | PTPN1PTPN2 | |
| SCHEMBL646001 | 0.80 | PTPN1 (0.61) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | PTPRS, PTPN5, PTPRR | PTPN1 17/4885PTPN2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.